검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART123 (Anti-CD123 LV redirected T cells, Anti-CD123 LV redirected T cells (CART123)) Stephan Grupp MD PhD·Acute Myeloid Leukemia (AML) 8 trials |
|---|---|
Overview Program | Anti-CD123 LV redirected T cells (CART123) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia (AML) |
Overview Indication | Acute Myeloid Leukemia (AML) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | CD19 and contains a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | CD123-targeted CAR T cell (CART123) is promising immunotherapy, but how to improve the complete remission (CR) rate and rescue potential hematopoietic toxicity still need to explore. |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG + AML.. Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG + AML is rare but has an extremely poor prognosis even with allo-HSCT in r… |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART123 (Anti-CD123 LV redirected T cells, Anti-CD123 LV redirected T cells (CART123)) Stephan Grupp MD PhD·Acute Myeloid Leukemia (AML) 8 trials |
|---|---|
Overview Program | Anti-CD123 LV redirected T cells (CART123) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia (AML) |
Overview Indication | Acute Myeloid Leukemia (AML) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | CD19 and contains a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | CD123-targeted CAR T cell (CART123) is promising immunotherapy, but how to improve the complete remission (CR) rate and rescue potential hematopoietic toxicity still need to explore. |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG + AML.. Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG + AML is rare but has an extremely poor prognosis even with allo-HSCT in r… |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교